Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity.

European journal of neurology - 1 Sept 2011

Depondt C, Godard P, Espel R S, Da Cruz A L, Lienard P, Pandolfo M

Abstract excerpt

BACKGROUND AND PURPOSE: It is widely acknowledged that individual response to antiepileptic drugs (AEDs) is influenced by genetic factors. However, most of the underlying genes and genetic variants remain unidentified to date. The purpose of this study is to examine the role of common variants in a number of candidate genes in the response to commonly prescribed AEDs. METHODS: We recruited 495 patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Epilepsy

Share to Genetic Association Studies

Share to Phenytoin

Share to Polymerase Chain Reaction

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 21338443
DOI: 10.1111/j.1468-1331.2011.03361.x

Genes

GSTM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity.PMID 21338443Read ↗

Pharmacogenetics and antiepileptic drugs.Semantic proximity Read ↗

CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.Semantic proximity Read ↗

An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effectsSemantic proximity Read ↗

Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.Semantic proximity Read ↗

CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatmentSemantic proximity Read ↗

Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.Semantic proximity Read ↗

Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients.Semantic proximity Read ↗

Epilepsy PharmacogeneticsSemantic proximity Read ↗

CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation.Semantic proximity Read ↗

Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients.Semantic proximity Read ↗

The clinical impact of pharmacogenetics on the treatment of epilepsy.Semantic proximity Read ↗

Role of Pharmacogenomics in Antiepileptic Drug Therapy: Current Status and Future Perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.